Abstract
Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main focus has shifted to structurally similar hydroxamic acid derivatives that target specific enzymes involved in cancer progression such as histone deacetylases, matrix metalloproteinases and also RNR.
Similar content being viewed by others
References
Dresler WFC, Stein R (1869) Ueber den Hydroxylharnstoff. Justus Liebigs. Ann Chem Pharmacol 150:242–252
Philips FS, Sternberg SS, Schwartz HS, Cronin AP, Sodergren JE, Vidal PM (1967) Hydroxyurea. I. Acute cell death in proliferating tissues in rats. Cancer Res 27:61–74
Rabes HM, Iseler G, Czichos S, Tuczek HV (1977) Synchronization of hepatocellular DNA synthesis in regenerating rat liver by continious infusion of hydroxyurea. Cancer Res 37:1105–1111
Rosenthal F, Wislicki L, Kollek L (1928) Uber die beziehungen von schwersten blutgiften zu abbauprodukten des eiweisses. Klin Wochenschr 7:972–977
Yarbro JW, Kennedy BJ, Barnum CP (1965) Hydroxyurea inhibition of DNA synthesis in ascites tumor. Proc Natl Acad Sci US 53:1033–1035
Young CW, Hodas S (1964) Hydroxyurea inhibitory effect on DNA metabolism. Science 146:1172–1174
Adams RLP, Lindsay JG (1967) Hydroxyurea. Reversal of inhibition and use as a cell-synchronizing agent. J Biol Chem 242:1314–1317
Krakoff IH, Brown NC, Reichard P (1968) Inhibition of ribonucleoside diphosphate reductase by hydroxyurea. Cancer Res 28:1559–1565
Mutschler E, Derendorf H (1995) Drug actions, basic principles and therapeutics aspects. Medpharm Scientific Publishers, Stuttgart
Charache S, Dover GJ, Moyer MA (1987) Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69:109
Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, NcMahon RP, Bonds DR (1995) Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 332:1317–1322
Schechter AN, Rodgers GP (1995) Sickle cell anemia: basic research reaches the clinic. N Engl J Med 332:1372–1374
Gao WY, Cara A, Gallo RC, Lori F (1993) Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 90:8925–8928
Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. New Eng J Med 332:1132–1136
Rosten M (1971) Hydroxyurea: a new antimetabolite in the treatment of psoriasis. Br J Dermatol 85:177–181
Donovan PB, Kaplan ME, Goldberg JD, Tatarsky I, Najean Y, Silberstein EB, Knospe WH, Laszlo J, Mack K, Berk PD, Wasserman LR (2006) Treatment of polycythemia vera with hydroxyurea. Am J Hematology 17:329–334
Hannessian S, Johnstone S (1999) Synthesis of hydroxamic esters via alkoxyaminocarbonylation of β-dicarbonyl compounds. J Org Chem 64:5896–5903
Kolasa T, Steward AO, Brooks CDW (1996) Asymetric synthesis of (R)-N-3-butyn-2-yl-N-hydroxyurea, a key intermediate for 5-lipoxygenase inhibitors. Tetrahedron: Asymetry 7:729–736
Nandy P, Lien EJ, Avramis VI (1999) Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (ara-C) and induction of cellular apoptosis. Anticancer Res 19:1625–1633
Kleeman A, Engel J, Kutscher B, Reichert D (2001) Pharmaceutical substances, synthesis, patents, applications, 4th edn. Thieme, Stuttgart
Slater ML (1973) Effect of reversible inhibition of deoxyribonucleic acid synthesis on the yeast cell cycle. J Bacteriol 113:263–270
Lassmann G, Thelander L, Graslund A (1992) EPR stopped-flow studies of the reaction of the tyrosyl radical of protein R2 from ribonucleotide reductase with hydroxyurea. Biochem Biophys Res Commun 188:879–887
Gwilt PR, Tracewell WG (1998) Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 34:347–358
Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP (1997) In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol 52:1081–1086
King SB (2003) The nitric oxide producing reactions of hydroxyurea. Curr Med Chem 10:437–452
Burrkitt MJ, Raft A (2006) Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood 107:2219–2222
Young CW, Schochetman G, Hodas S, Balis ME (1967) Inhibition of DNA synthesis by hydroxyurea: structure–activity relationship. Cancer Res 27:535–540
Elford HR, Wampler GL, van’t Riet B (1979) New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 39:844–851
Parrish DA, Zou Z, Allen CL, Day CS, King SB (2005) A convenient method for the synthesis of N-hydroxyureas. Tetrahedron Lett 46:8841–8843
Scozzafava A, Supuran CT (2003) Hydroxyurea is a carbonic anhydrase inhibitor. Bioorg Med Chem 11:2241–2246
Elford H (1968) Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 33:129–135
Moore EC (1969) The effect of ferrous ion and dithioerythritol on inhibition by hydroxyurea of ribonucleotide reductase. Cancer Res 29:291–295
Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK (1998) A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood 91:1533–1541
Donehower RC (1992) An overview of the clinical experience with hydroxyurea. Semin Oncol 19:11–19
Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O’Brien S (1998) Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol 16:2321–2331
Kacew S (1989) Drug toxicity and metabolism in pediatrics. CRC Press, Boca Raton
Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O’Brien S, Markowitz A, Kantarjian H (1999) Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35:109–118
Sirieix ME, Debure C, Baudot N, Dubertret L, Roux ME, Morel P, Frances C, Loubeyres S, Beylot C, Lambert D, Humbert P, Gauthier O, Dandurand M, Guillot B, Vaillant L, Lorette G, Bonnetblanc JM, Lok C, Denoeux JP (1999) Leg ulcers and hydroxyurea. Arch Dermatol 135:818–820
Richard M, Truchetet F, Friedel J, Leclech C, Heid E (1989) Skin lesions simulating chronic dermatomyositis during long-term hydroxyurea therapy. J Am Acad Dermatol 21:797–799
Velez A, Lopez-Rubio F, Moreno JC (1998) Chronic hydroxyurea-induced dermatomyositis-like eruption with severe dermal elastosis. Clin Exp Dermatol 23:94–95
Gropper CA, Don PC, Sadjadi MM (1993) Nail and skin hyperpigmentation associated with hydroxyurea therapy for polycythemia vera. Int J Dermatol 32:731–733
De Montalembert M, Belloy M, Bernaudin F, Gouraud F, Capdeville R, Mardini R, Philippe N, Jais JP, Bardakdijan J, Ducrocq R, Maier-Redelsperger M, Elion J, Labie D, Girot R (1997) Three-year follow-up of hxdroxyurea treatment in severely ill children with sickle cell disease. J Pediatr Hematol/Oncol 19:313–318
Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic. Blood 94:1517–1536
Goldman JM (1997) Optimizing treatment for chronic myeloid leukemia. New Engl J Med 337:270–271
Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgeroth G, Maywald O, Hasford J, Reiter A, Hossfeld DK, Kolb HJ, Löffler H, Pralle H, Quei er W, Griesshammer M, Nerl C, Kuse R, Tobler A, Eimermacher H, Tichelli A, Aul C, Wilhelm M, Fischer JT, Perker M, Scheid C, Schenk M, Wei J, Meier CR, Kremers S, Labedzki., Schmeiser T, Lohrmann H-P, Heimpel P, the German CML-Study Group (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529–1537
Piver MS, Barlow JJ, Vongtama V, Blumenson L (1983) Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix. A randomized double-blind study. Am J Obstet Gynecol 147:803–808
Hreshchyshyn MM, Aron BS, Boronow RC, Franklin EW 3rd, Shingleton HM, Blessing JA (1979) Hydroxyurea or placebo combined with radiation to treat stages IIIB and IV cervical cancer confined to the pelvis. Int J Radiat Oncol Biol Phys 5:317–322
Schrell UMH, Rittig MG, Koch U, Marschalek R, Anders M (1996) Hydroxyurea for treatment of unresectable meningiomas. Lancet 348:888–889
Schrell UMH, Rittig MG, Anders M, Kiesewetter F, Marschalek R, Koch UH et al (1997) Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg 86:845–852
Cammack KV, Taylor RM (1972) Advanced neoplasm of head and neck. Treatment with combined radiation and chemotherapy. Rocky Mt Med J 69:54–56
Richards GJ, Chambers RG (1973) Hydroxyurea in the treatment of neoplasm of head and neck. Am J Surg 126:513–518
Hussey DH, Abrams P (1975) Combined therapy in advanced head and neck cancer: hydroxyurea and radiotherapy. Prog Clin Cancer 6:79–86
Lerner HJ (1978) Concomitant hydroxyurea and irradiation. Clinical experience with 100 patients with advanced head and neck cancer at Pennsylvania Hospital. Am J Surg 134:505–550
Blasberg RG, Patlack C, Fenstermacher JD (1975) Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195:73–83
Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer therapeutics. Curr Oncol 15:237–243
Rothenberg ML, Nelson AR, Hande KR (1999) New drugs on the horizon: matrix metalloproteinase inhibitors. Stem Cells 17:237–240
Mahlknecht U, Hoelzer D (2000) Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med 6:623–644
Cress WD, Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184:1–16
Marks PA, Rifkind RA, Richon VM, Breslow R (2001) Inhibitors of histone deacetylase are potentially effective anticancer agents. Clin Cancer Res 7:759–760
Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287–299
Duvic M, Vu J (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T cell lymphoma. Expert Opin Investig Drugs 16:1111–1120
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18:1135–1149
Avendano C, Menendez JC (2008) Medicinal chemistry of anticancer drugs. Elsevier, Amsterdam
Cross JB, Duca JS, Kaminski JJ, Madison VS (2002) The active site of a zinc-dependent metalloproteinase influences the computed pKa of ligands coordinated to the catalytic zinc ion. J Am Chem Soc 124:11004–11007
Botos I, Scapozza L, Zhang D, Liotta LA, Meyer EF (1996) Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc Nat Acad Sci USA 93:2749–2754
Rasmussen HS, Teicher BA (eds) (1999) Antiangiogenic agents in cancer therapy. Humana Press, Totowa
Brown PD (1999) Clinical studies with matrix metalloproteinase inhibitors. APMIS 107:174–180
Wojtowicz-Praga S, Low J, Marshall J, Ness E, Dickson R, Barter J, Sale M, McCann P, Moore J, Cole A, Hawkins MJ (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drugs 14:193–202
Macaulay VM, O’Byrne KJ, Saunders MP, Braybrooke JP, Long L, Gleeson F, Mason CS, Harris AL, Brown P, Talbot DC (1999) Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5:513–520
Beattie GJ, Smyth JF (1998) Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites. Clin Cancer Res 4:1899–1902
Rothenberg ML, Nelson AR, Hande KR (1998) New drugs on the horizon: matrix metalloproteinase inhibitors. Oncologist 3:271–274
Shalinsky DR, Brekken J, Zou H, McDermott CD, Forsyth P, Edwards D, Margosiak S, Bender S, Truitt G, Wood A, Varki NM, Appelt K (1999) Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 878:236–270
Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14:1497–1511
Finnin MS, Donigian JR, Venitz J, Figg WD (1999) Rational development of histone deacetylase homologue bound to TSA and SAHA. Nature 401:188–193
Acharya MR, Sparreboom A, Venitz J, Figg WD (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68:917–932
Monneret C (2005) Histone deacetylase inhibitors. Eur J Med Chem 40:1–13
Lin HY, Chen CS, Lin SP, Weng JR, Chen CS (2006) Targeting histone deacetylase in cancer therapy. Med Res Rev 26:397–413
Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T (1997) Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 241:142–150
Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, Furuichi K, Sakai T (2003) p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 22:7762–7773
Takai N, Ueda T, Nishida M, Nasu K, Narahara H (2008) Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells. Int J Mol Med 21:109–115
Ouaissi M, Ouaissi A (2006) Histone deacetylase enzymes as potential drug targets in cancer and parasitic diseases. Biomed Biotechnol 2006:13474–13477
Hoekstra R, Eskens FALM, Verweij J (2001) Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 6:415–427
Zucker S, Cao J, Chen W-T (2000) Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642–6650
Lee M-J, Kim YS, Kummar S, Giaccone G, Trepel JB (2008) Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol 20:639–649
Santini V, Gozzini A, Ferrari G (2007) Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8:383–393
Lindemann RK, Gabrielli B, Johnstone RW (2004) Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3:779–788
Marks PA, Richon VM, Miller T, Kelly WK (2004) Histone deacetylase inhibitors. Adv Cancer Res 91:137–168
Rosato RR, Grant S (2004) Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13:21–38
Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495–528
Kelly WK, Marks AP (2005) Drug insight: Histone deacetylase inhibitors development of the new targeted anticancer agent suberolyanilide hydroxamic acid. Nat Clin Pract Oncol 2:1–8
Munster PN, Troso-Sandoval T, Rosen N (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492–8497
Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Gandara DR, Aparicio A, Somlo G, Wong C (2008) A phase ii trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium Study. Clin Cancer Res 14:7138–7142
Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 49:502–507
Crump M, Coiffier B, Jacobsen ED, Sun L, Ricker JL, Xie H, Frankel SR, Randolph SS, Cheson BD (2008) Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B cell lymphoma. Ann Oncol 19:964–969
Modesitt SC, Sill M, Hoffman JS, Bender DP, Gynecologic Oncology Group (2008) A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 109:182–186
Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR (2008) Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26:81–87
Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP (2007) Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 13:3605–3610
Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G, Moses MA (2000) Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 97:3884–3889
Coussens LM, Fingleton B, Lynn M (2002) Matrisian matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295:2387–2392
Boasberg P, Harbaugh BL, Eisenberger M, Harris J, Langleben A, Ahnmann F, Roth B, Berkheimer M, Ramussen H (1997) Marimastat in patients with hormone refractory prostate cancer: a dose-finding study. Proc Am Soc Clin Oncol 16:316a
Fielding J, Scholefield J, Stuart R, Hawkins R, McCulloch P, Maughan T, Seymour M, Van Custem E, Thorlacius-Ussing C, Hovendal C (2000) A randomized double-blind placebo-controlled study of marimistat in patients with inoperable gastric adenocarcinoma. Proc Am Soc Clin Oncol 19:240a
Price A, Shi Q, Morris D, Wilcox ME, Brasher PMA, Rewcastle NB, Shalinsky D, Zou H, Appelt K, Johnston RN, Yong VW, Edwards D, Forsyth P (1999) Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 5:845–854
Santos O, McDermott CD, Daniels R, Appelt K (1997) Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin Exp Metastasis 15:499–508
Bissett D, O’Byrne KJ, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang MH, Collier MA, Shepherd FA (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 23:842–849
Opacic N, Barbaric M, Zorc B, Cetina M, Nagl A, Frkovic D, Kralj M, Pavelic K, Balzarini J, Andrei G, Snoeck R, De Clercq E, Raic-Malic S, Mintas M (2005) The novel l- and d-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, and cytostatic and antiviral activity evaluations. J Med Chem 48:475–482
Perkovic I, Butula I, Zorc B, Hock K, Kraljevic Pavelic S, Pavelic K, De Clercq E, Balzarini J, Mintas M (2008) Novel lipophilic hydroxyurea derivatives: synthesis, cytostatic and antiviral activity evaluations. Chem Biol Drug Des 71:546–553
Yoshida M, Horinouchi S, Beppu T (1995) Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays 17:423–430
Richon VM, Emiliani S, Verdin E, Webb J, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3303–3307
Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM (1999) Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 19:4999–5005
Acknowledgments
This paper was financially supported by the Croatian Ministry of Science, Education and Sport’s grants entitled “Molecular characteristic of myofibroblasts derived from Dupuytren’s contracture” (098-0982464-2393). We greatly appreciate the financial help of the Foundation of Croatian Academy of Sciences and Arts.
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Saban, N., Bujak, M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol 64, 213–221 (2009). https://doi.org/10.1007/s00280-009-0991-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-0991-z